Group 1: Company Positioning and Market Overview - The company is a leader in high-end analytical instruments in China, providing comprehensive solutions across various sectors including environmental safety, industrial processes, and water management [2] - The company has made significant applications in industries such as petrochemicals, steel, rare earths, and nuclear power, with plans to expand into new fields like semiconductors [3] Group 2: Research and Development - In 2019, the company's R&D investment in high-end analytical instruments accounted for approximately 8% of its revenue, with a total R&D investment exceeding 1.9 billion [3] - The company has over 1,000 R&D personnel and has developed more than 20 new technology platforms, marking a transition from a technology reserve phase to a harvest phase in its high-end analytical instrument business [3] Group 3: Impact of COVID-19 - The pandemic significantly affected government bidding processes, leading to challenges in business operations and a substantial decline in Q1 revenue compared to the previous year [4] - Despite the difficulties, the company has seen an increase in order volume, although execution has been delayed [4] Group 4: Financial Performance and Challenges - The major reasons for the significant decline in the company's performance in 2019 included provisions and excessive competition [5] - The company is working to improve these factors in 2020 to return to a stable business trajectory [5] Group 5: PPP Business and Risk Management - The company has been involved in PPP projects since 2016, focusing on environmental equipment development and management [5] - Most PPP projects have an investment scale controlled within 1 billion, with about 50% of projects under 500 million [6] - The capital contribution ratio for projects is controlled at around 20% of total investment, with the company contributing no more than 90% of the capital [6] Group 6: Market Expansion and Future Plans - The company aims to strengthen import substitution in the high-end analytical instrument sector, with applications in various fields including environmental monitoring and smart manufacturing [7] - Plans are in place to develop products for the semiconductor manufacturing sector, with a focus on meeting the industry's specific instrument needs [8] Group 7: Technical Capabilities and Product Development - The company has a strong capability in optical, mass spectrometry, and other analytical technologies, which are applicable in semiconductor laboratories and monitoring [9] - The company is well-positioned to meet the demands of the semiconductor industry, leveraging its existing technologies and R&D capabilities [9]

编号：2020-002 证券代码：300203 证券简称：聚光科技 聚光科技（杭州）股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|-------------------------|---------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | □ 一对一沟通 | | | □ 其他 | | | 参与单位名称及 | | 浙商证券 佘骞 东亚前海证券 杨柳青 | | 人员姓名 | | | | 时间 | 2020 年 5 月 27 | 日下午 3:30 | | 地点 | 公司会议室 | | | 上市公司接待人 | | 公司创始人 王健 董事会秘书 田昆仑 | | 员 | | | | 投资者关系活动 | 1 、公司 PPP | 业务的状况？ | | 主要内容介绍 | 答：公司自开展 | PPP 业务 ...

7P | EXPEC 科学仪器与半导体 cninf 55 www.cntb.com.cn 半导体产业链 英特尔 展 讯 SK 海力士 RDA 应用材料 中电科电子装备 原子力显微镜、X射线衍射仪、电子衍射法ED（反射高能电子衍射RHEED、低能电子衍射LEED）、透射电子显 华大半导体 类光 Lam Research 浙江昌盛机电 微镜、扫描电子显微镜、X射线能量色散谱EDS、显微激光拉曼光谱仪、角分辨光电子能谱ARPES、电学性能表 博通 大唐电信 Tokyo Electror 深圳捷佳伟创 高通 国民技术 ASML 北京北方华创 征、光致发光PL、电化学工作站、傅里叶变换红外光谱仪、拉曼光谱仪、离子色谱仪、电子探针分析仪、热重分 硅片 东芝 汇页科技 KLA-Tencor 中散半导体设备 析仪、X射线光电子能谱、俄歇电子能谱、台阶仪、透射光谱（紫外-可见光-近红外分光光度计、双光束紫外可 德州仪器 中星徽电子 上海微电子 Screen 见分光光度计）、荧光光谱、扫描探针显微镜、特斯拉仪 英伟达 北京君正 SEMES 北京京运通 西部數据 豪威科技 日 ▽高频 浙江天通吉成 恩智浦 盛美半导体 敦泰电子 目 ...

证券代码：300203 证券简称：聚光科技 聚光科技（杭州）股份有限公司投资者关系活动记录表 编号：2020-005 | --- | --- | --- | |----------------|----------------|-------------------------------------------------------------| | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | ■ 现场参观 | □ 一对一沟通 | | | □ 其他 | | | 参与单位名称及 | | 恒泰证券 杨骥宇；万联证券 黄星；凯银投资 王博；盈沣投资 姚 | | 人员姓名 | | 跃；杭州久协投资 董小耀；之江资本 王文明；国盛华运 傅浩； | | | | 杭州宽合投资 周小峰；恒天明泽 徐枝杰；浙江御河投资 何建 | | | | 良；惟像资本 赵科伟；东北证券 黄克康；杭新投基金 方皓；上 | | | | 海凯梵投资 顾远；上海朴易资产 宋伟；国泰君安证券 戴俊彦；国 | ...

证券代码：300203 证券简称：聚光科技 编号：2018-001 聚光科技（杭州）股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |----------------|----------------|-------|-----------------------------------------| | | | | | | 投资者关系活动 | □ 特定对象调研 | | □ 分析师会议 | | 类别 | □ 媒体采访 | | □ 业绩说明会 | | | □ 新闻发布会 | | □ 路演活动 | | | □ 现场参观 | | □ 一对一沟通 | | | ■ | | 其他 （投资者接待日活动） | | 参与单位名称及 | | | 国海证券 季翀 龙全投资 张宇麟 | | 人员姓名 | | | 炬元资产 衣正杰 元葵投资 陈立 | | | | | 中金公司 张梓丁 宝基股权投资基金 王伟霄 | | | | | 海通证券 耿耘 国海证券 赵越 | | | | | 汇丰前海 李博男 渤海证券 刘蕾 | | | | | 渤海银行 余清原 中天证券 梁鹏 | | | | | 中原证券 ...

证券代码：300203 证券简称：聚光科技 编号：2021-001 | --- | --- | --- | |----------------|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | 投资者关系活动 | ■ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | □ 一对一沟通 | | | □ 其他 | | | 参与单位名称及 | | 王沛（浙金产融）、闫亚洲（浙江信得宝创投）、董怡晨（玄武 | | 人员姓名 | | 智能）、叶云友（青岛玄武盛和基金）、王连民（杭州倍格投资）、 | | | | 何立娜（杭州倍格投资）、韩旭 ...

Group 1: Company Overview and Market Position - 聚光科技 is a leading domestic manufacturer of analytical instruments, focusing on high-end technology development [3] - The company aims to become a global leader in scientific instrument manufacturing, with a mission to fulfill customer dreams in the analysis and detection field [4] Group 2: Research and Development - The company has made significant R&D progress in life science instruments, including mass spectrometry, chromatography, and spectroscopy [3] - Future plans include customized and differentiated services to address market challenges, particularly in the medical application of mass spectrometry [3] Group 3: Business Strategy and Growth Drivers - The growth of 聚光科技 is driven by favorable national economic conditions, policy support for innovation, and the company's ability to seize market opportunities [4] - The company plans to expand its product offerings and market segments through continuous innovation and technology breakthroughs [4] Group 4: Talent Management and Organizational Structure - 聚光科技 emphasizes talent cultivation and management, implementing a tiered equity incentive system to motivate employees [4] - The company employs a matrix management structure to facilitate collaboration across different product lines and market segments [4] Group 5: Pricing Strategy and Profitability - The pricing strategy for scientific instruments is competitive, with higher prices for innovative products and stable overall gross margins [5] - The gross margin for individual scientific instruments is relatively high, while comprehensive solutions may have lower margins due to additional components [5] Group 6: Production Capacity and Efficiency - The production capacity of scientific instruments is not a major challenge for manufacturing companies, as the focus is on market share and efficiency [5] - The income-output ratio varies with the company's development stage, with lower ratios during rapid growth phases due to higher investments in R&D and sales [5]

Group 1: Financial Performance - The revenue from environmental governance equipment and engineering has seen growth, but the gross profit margin has significantly declined due to increased market competition [2][3] - The revenue for the first half of the year from instruments is approximately 859 million, with growth in environmental monitoring and industrial monitoring segments [3][4] - The net profit for the subsidiary Puyue in the first half is -74 million, and for another subsidiary, it is -13 million, primarily due to ongoing project costs without new income [4] Group 2: Business Operations - The order growth rate for the subsidiary Puyue is faster than revenue growth, affected by project implementation delays due to the pandemic [3] - The company’s various business departments have shown growth in instrument sales, particularly in the environmental and industrial monitoring sectors [3][4] - The company is focusing on high-end analytical instruments, which typically experience a 3-5 year ramp-up period before significant revenue growth [5] Group 3: Market Trends and Strategy - The overall market demand for environmental and scientific instruments remains stable, despite the impact of the pandemic [4][5] - The company aims to leverage market opportunities and its strengths to shorten the ramp-up period and enhance competitive advantages across multiple technology platforms [5] - The financial reporting of PPP projects is reflected in non-current assets and long-term receivables on the balance sheet [4]

Group 1: Financial Performance and Projections - The company expects the highest revenue contribution in Q4, with approximately two-thirds of the revenue coming from contracts signed in previous quarters [3] - The loss in the first three quarters is attributed to delayed revenue recognition due to the pandemic and significant R&D investments [3] - The company has a reasonable budget completion progress for the year [3] Group 2: Impact of Subsidized Loans - The implementation of subsidized loans is expected to accelerate existing demand from universities, with new budget requirements likely to be released by the end of the year [3] - Approximately 10% of the company's scientific instrument sales are expected to come from universities [4] - The demand for instruments from key universities (211 and 985) is anticipated to be more specialized, while provincial universities will have broader procurement needs [4] Group 3: Competitive Landscape - The policy encourages the purchase of domestic brands, but decisions remain with the universities based on their research needs and preferences [4] - The company aims to enhance its product variety and quality to better match market demands and gain recognition [4] Group 4: Market Outlook - The pandemic has caused delays in orders, but the impact on revenue recognition is more significant than on order volume [4] - The environmental instrument sector is expected to remain stable, with government investments continuing despite the pandemic [4] - The company plans to maintain competitiveness in the environmental sector through a diverse product and business platform [4] Group 5: Talent Acquisition and Management - The company recognizes the need for new talent in emerging sectors like education and healthcare, while existing staff will continue to manage their current domains [5] - The sales management model is similar across sectors, with a focus on product competitiveness and market coverage [5]

Financial Performance - The company's revenue for Q3 2022 was ¥823,522,842.54, representing a 14.66% increase year-over-year[7] - The net profit attributable to shareholders was -¥23,115,029.13, a 54.27% decline compared to the same period last year[7] - The net profit after deducting non-recurring gains and losses was -¥38,342,806.39, a 34.12% decrease year-over-year[7] - The company reported a basic earnings per share of -¥0.052, a 54.16% decline compared to the same period last year[7] - The net profit for the third quarter was -142,037,972.59, compared to -62,111,252.96 in the previous year, indicating a significant increase in losses[35] - The total operating profit was -219,399,373.10, which is a decline from -141,203,830.63 year-over-year[35] - The company reported a basic and diluted earnings per share of -0.247, worsening from -0.138 in the previous year[37] - The company recorded a total comprehensive income of -141,253,720.92, compared to -64,004,796.33 in the previous year[35] Assets and Liabilities - The total assets at the end of Q3 2022 amounted to ¥10,764,823,564.34, reflecting a 4.52% increase from the end of the previous year[7] - The equity attributable to shareholders decreased by 0.78% to ¥3,487,987,529.73 compared to the end of the previous year[7] - The company's total assets reached ¥10,764,823,564.34, up from ¥10,299,570,001.85[30] - Total liabilities increased to ¥6,919,813,336.30 from ¥6,392,570,812.95, indicating a rise in financial obligations[30] Cash Flow and Investments - The cash flow from operating activities was -¥455,264,813.46, showing a 7.69% decline year-over-year[7] - Cash flow from operating activities showed a net outflow of -455,264,813.46, compared to -422,759,085.30 in the same period last year[38] - The net cash flow from investing activities was -93,324,325.73, compared to -638,928,201.41 in the previous year, indicating improved cash management[41] - Financing activities generated a net cash inflow of 327,819,589.82, down from 471,080,669.54 in the previous year[41] Revenue and Costs - The company reported total operating revenue of ¥2,174,810,094.29 for the current period, an increase from ¥2,087,366,827.04 in the previous period[31] - Total operating costs increased to ¥2,500,942,018.60, compared to ¥2,351,026,214.38 in the previous period, with operating costs specifically rising to ¥1,226,439,074.65 from ¥1,167,491,321.90[31] - The company’s total revenue from operating activities was 2,400,110,623.16, compared to 2,204,608,934.99 in the previous year, reflecting growth in operational performance[38] Shareholder Information - The total number of common shareholders at the end of the reporting period was 9,840, with the top ten shareholders holding a combined 17.62% and 11.84% of shares respectively[16] - The top two shareholders, Zhejiang Ruiyang Technology Co., Ltd. and Zhejiang Pudu Technology Co., Ltd., hold 79,728,747 shares and 53,561,600 shares respectively[16] - The company implemented an employee stock ownership plan in 2022, with a maximum holding of 6,407,600 shares, sourced from repurchased A-shares[20] - The company received a total of 6,407,600 shares transferred to the employee stock ownership plan at a price of 12.64 RMB per share[21] Contracts and Growth - The total amount of new contracts signed in the first three quarters of 2022 was approximately 2.9 billion RMB, representing a year-on-year increase of about 16%[21] - The subsidiary, Puyu Medical Technology Co., Ltd., signed new contracts worth approximately 1 billion RMB, a 45% increase year-on-year, contributing significantly to the company's growth[21] - The company’s revenue from Puyu Technology was approximately 550 million RMB, with a net profit of about -100 million RMB[21] - The company’s registered capital for Puyu Medical increased from 17,094,017.10 RMB to 20,110,608.35 RMB after introducing financial investors[21] Strategic Focus - The company aims to enhance its core technology and develop multiple technical platforms to become a leading brand in high-end instrument equipment[24] - The company is focused on expanding its market presence through new laboratory solutions and addressing various sectors including life sciences and environmental safety[24] - The company is actively negotiating the divestment of certain PPP projects to optimize its asset-liability structure[21] - The government announced policies to support equipment upgrades in specific sectors, which is expected to boost demand for the company's products[21] Research and Development - Research and development expenses for the current period were ¥477,273,011.63, compared to ¥411,296,121.51 in the previous period, showing a commitment to innovation[31] Inventory and Receivables - The company's cash and cash equivalents decreased to ¥1,294,760,567.95 from ¥1,421,497,920.82[25] - Accounts receivable increased to ¥1,380,839,887.89 from ¥1,309,358,354.44, indicating a growth in credit sales[25] - Inventory rose significantly to ¥1,731,991,580.74 from ¥1,358,215,089.00, reflecting increased production or stockpiling[25] Long-term Receivables and Construction - The long-term receivables increased by 95.22% to ¥667,907,379.64 due to the recognition of long-term receivables from PPP projects[12] - The construction in progress rose by 93.57% to ¥75,477,658.65, primarily due to increased investment in a new base by a subsidiary[12]